{"entity":{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","aka":[],"tldr":"Kyowa Kirin is a Japanese biopharmaceutical company whose oncology products include mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma and toremifene (Fareston) for metastatic breast cancer.","summary":"Kyowa Kirin, based in Tokyo, listed as 4151.T and part of the Kirin group, is a Japanese biopharmaceutical company whose oncology products include mogamulizumab, sold as Poteligeo, for cutaneous T-cell lymphoma and toremifene, sold as Fareston, for metastatic breast cancer. It developed the anti-CCR4 antibody mogamulizumab, markets Fareston in the United States, and also sells burosumab as Crysvita and G-CSF products in Japan. OnCo links it to the toremifene drug record. Whether a CCR4 antibody can find uses beyond rare T-cell lymphomas is the open question for its oncology franchise. Toremifene has its own page.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Kyowa_Kirin","links":[{"label":"Official website","url":"https://www.kyowakirin.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["ccr4"],"drugs":["mogamulizumab","toremifene","burosumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07629726","nct07623616"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.kyowakirin.com","ticker":"4151.T","investors":[],"funding":[]},"route":"/companies/kyowa-kirin/","neighbours":{"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"}],"drug":[{"id":"burosumab","kind":"drug","name":"Burosumab","route":"/drugs/burosumab/"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"},{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/"}],"trial":[{"id":"nct07629726","kind":"trial","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","route":"/trials/nct07629726/"},{"id":"nct07623616","kind":"trial","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","route":"/trials/nct07623616/"},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/"}],"company":[{"id":"mei-pharma","kind":"company","name":"MEI Pharma","route":"/companies/mei-pharma/"}],"paper":[{"id":"paper-ux023t-cl201-jan-de-beur-jbmr-2021","kind":"paper","name":"Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)","route":"/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/"}]}}